间充质干细胞在骨髓增生异常综合征发病机制中的研究进展

doi:10.16150/j.1671-2870.2018.01.024

摘要/Abstract

关键词: 间充质干细胞, 骨髓增生异常综合征, 增殖异常, 疾病进展, 免疫调控

中图分类号:

R733.3

师蕾, 常春康. 间充质干细胞在骨髓增生异常综合征发病机制中的研究进展[J]. 诊断学理论与实践, 2018, 17(01): 123-126.

[1] Schroeder T, Geyh S, Germing U, et al.Mesenchymal stromal cells in myeloid malignancies[J]. Blood Res,2016,51(4):225-232.
[2] Wang J, Xiao Z.Mesenchymal stem cells in pathogenesis of myelodysplastic syndromes[J]. Stem Cell Investig,2014,1:16.
[3] Rathnayake AJ, Goonasekera HW, Dissanayake VH.Phenotypic and Cytogenetic Characterization of Mesen-chymal Stromal Cells in De Novo Myelodysplastic Syndromes[J]. Anal Cell Pathol (Amst),2016,2016:8012716.
[4] Kim Y, Jekarl DW, Kim J, et al.Genetic and epigenetic alterations of bone marrow stromal cells in myelodysplastic syndrome and acute myeloid leukemia patients[J]. Stem Cell Res,2015,14(2):177-184.
[5] Kouvidi E, Stratigi A, Batsali A, et al.Cytogenetic evalua-tion of mesenchymal stem/stromal cells from patients with myelodysplastic syndromes at different time-points during ex vivo expansion[J]. Leuk Res,2016,43:24-32.
[6] Liu Q, Zhu H, Dong J, et al.Defective proliferative potential of MSCs from pediatric myelodysplastic syndrome patients is associated with cell senescence[J]. Int J Clin Exp Pathol,2015,8(10):13059-13066.
[7] Fei CM, Gu SC, Zhao YS, et al.Osteogenic Differentiation Potential of Bone Marrow Mesenchymal Stem Cells in Patients with Myelodysplastic Syndromes[J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi,2015,23(3):750-755.
[8] Aanei CM, Flandrin P, Eloae FZ, et al.Intrinsic growth deficiencies of mesenchymal stromal cells in myelodysplastic syndromes[J]. Stem Cells Dev,2012,21(10):1604-1615.
[9] Almeida MI, Silva AM, Vasconcelos DM, et al.miR-195 in human primary mesenchymal stromal/stem cells regulates proliferation, osteogenesis and paracrine effect on angiogenesis[J]. Oncotarget,2016,7(1):7-22.
[10] Geyh S, Oz S, Cadeddu RP, et al.Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells[J]. Leukemia,2013, 27(9):1841-1851.
[11] Fei C, Zhao Y, Gu S, et al.Impaired osteogenic differentiation of mesenchymal stem cells derived from bone marrow of patients with lower-risk myelodysplastic syndromes[J]. Tumour Biol,2014,35(5):4307-4316.
[12] Fei C, Guo J, Zhao Y, et al.Notch-Hes pathway mediates the impaired osteogenic differentiation of bone marrow mesenchymal stromal cells from myelodysplastic syndromes patients through the down-regulation of Runx2[J]. Am J Transl Res,2015,7(10):1939-1951.
[13] Fei C, Zhao Y, Guo J, et al.Senescence of bone marrow mesenchymal stromal cells is accompanied by activation of p53/p21 pathway in myelodysplastic syndromes[J]. Eur J Haematol,2014,93(6):476-486.
[14] Horiguchi H, Kobune M, Kikuchi S, et al.Extracellular vesicle miR-7977 is involved in hematopoietic dysfunction of mesenchymal stromal cells via poly(rC) binding protein 1 reduction in myeloid neoplasms[J]. Haematologica, 2016,101(4):437-447.
[15] Pavlaki K, Pontikoglou CG, Demetriadou A, et al.Impaired proliferative potential of bone marrow mesenchymal stromal cells in patients with myelodysplastic syndromes is associated with abnormal WNT signaling pathway[J]. Stem Cells Dev,2014,23(14):1568-1581.
[16] Zhao Y, Wu D, Fei C, et al.Down-regulation of Dicer1 promotes cellular senescence and decreases the differentiation and stem cell-supporting capacities of mesenchymal stromal cells in patients with myelodysplastic syndrome[J]. Haematologica,2015,100(2):194-204.
[17] Roversi FM, Lopes MR, Machado-Neto JA, et al.Serine protease inhibitor kunitz-type 2 is downregulated in myelodysplastic syndromes and modulates cell-cell adhesion[J]. Stem Cells Dev,2014,23(10):1109-1120.
[18] Poitz DM, Stölzel F, Arabanian L, et al.MiR-134-media-ted β1 integrin expression and function in mesenchymal stem cells[J]. Biochim Biophys Acta,2013,1833(12):3396-3404.
[19] Ferrer RA, Wobus M, List C, et al.Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide[J]. Haematologica,2013,98(11):1677-1685.
[20] Scharenberg C, Giai V, Pellagatti A, et al.Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations[J]. Haematologica,2017,102(3):498-508.
[21] Raaijmakers MH, Mukherjee S, Guo S, et al.Bone progenitor dysfunction induces myelodysplasia and secon-dary leukaemia[J]. Nature,2010,464(7290):852-857.
[22] Raaijmakers MH.Disease progression in myelodysplastic syndromes: do mesenchymal cells pave the way?[J]. Cell Stem Cell,2014,14(6):695-697.
[23] Zou J, Hong Y, Tong Y, et al.Sonic hedgehog produced by bone marrow-derived mesenchymal stromal cells supports cell survival in myelodysplastic syndrome[J]. Stem Cells Int,2015,2015:957502.
[24] Medyouf H, Mossner M, Jann JC, et al.Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit[J]. Cell Stem Cell,2014,14(6):824-837.
[25] Schroeder T, Geyh S, Germing U, et al.Mesenchymal stromal cells in myeloid malignancies[J]. Blood Res,2016, 51(4):225-232.
[26] Zambetti NA, Ping Z, Chen S, et al.Mesenchymal Inflammation drives genotoxic stress in hematopoietic stem cells and predicts disease evolution in human pre-leukemia[J]. Cell Stem Cell,2016,19(5):613-627.
[27] Oliveira FM, Lucena-Araujo AR, Favarin Mdo C, et al.Differential expression of AURKA and AURKB genes in bone marrow stromal mesenchymal cells of myelodysplastic syndrome: correlation with G-banding analysis and FISH[J]. Exp Hematol,2013,41(2):198-208.
[28] Lubkova ON, Tzvetaeva NV, Momotyuk KS, et al.VCAM-1 expression on bone marrow stromal cells from patients with myelodysplastic syndromes[J]. Bull Exp Biol Med,2011,151(1):13-15.
[29] Wang Z, Tang X, Xu W, et al.The different immunoregulatory functions on dendritic cells between mesenchymal stem cells derived from bone marrow of patients with low-risk or high-risk myelodysplastic syndromes[J]. PLoS One,2013,8(3):e57470.
[30] Liu LH, Chen H, Chen B, et al.Immuno-suppressive effects on T cells mediated by mesenchymal stem cells from patients with myelodysplastic syndrome[J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi,2008,16(2):299-304.
[31] Muntión S, Ramos TL, Diez-Campelo M, et al.Microvesicles from mesenchymal stromal cells are involved in HPC-microenvironment crosstalk in myelodysplastic patients[J]. Plos One,2016,11(2):e0146722.
[32] Xiao Y, Wang Y, Li L, et al.Homing of chloromethylbenzoyl ammonia-labeled bone marrow mesenchymal stem cells in an immune-mediated bone marrow failure mouse model in vivo[J]. Genet Mol Res,2014,13(1):11-21.
[33] Maurizi G, Mattiucci D, Mariani M, et al.DNA demethylating therapy reverts mesenchymal stromal cells derived from high risk myelodysplastic patients to a normal phenotype[J]. Br J Haematol,2017,177(5):818-822.
[34] Lazarus HM, Haynesworth SE, Gerson SL, et al.Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use[J]. Bone Marrow Transplant,1995,16(4):557-564.

间充质干细胞在骨髓增生异常综合征发病机制中的研究进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	曹红刚, 苏媛, 赵强, 薛锋, 汉英, 王存邦, 白海, 吴涛. 肝炎相关重症再生障碍性贫血诊治一例报道并文献复习[J]. 诊断学理论与实践, 2021, 20(06): 579-581.
[2]	王柔嘉, 常春康. 调节性T细胞在骨髓增生异常综合征危险分层中的研究进展[J]. 诊断学理论与实践, 2021, 20(02): 221-224.
[3]	叶成林, 姚永华, 陈真, 贾麟. 骨髓活检塑胶包埋在以单纯血小板减少为表现的骨髓增生异常综合征诊断中的应用价值[J]. 诊断学理论与实践, 2020, 19(02): 177-181.
[4]	吴凌云, 常春康. 骨髓增生异常综合征的诊治最新进展[J]. 诊断学理论与实践, 2019, 18(06): 623-629.
[5]	杜云志, 冯菁华, 常春康. 二代测序技术在骨髓增生异常综合征临床诊断和治疗决策中的应用进展[J]. 诊断学理论与实践, 2019, 18(06): 685-671.
[6]	宋丹丹, 常春康, 郭娟, 许峰, 赵佑山, 吴凌云. 骨髓增生异常综合征患者骨髓巨噬细胞百分比异常及其意义[J]. 诊断学理论与实践, 2018, 17(04): 439-443.
[7]	肖志坚. 骨髓增生异常综合征的诊断[J]. 诊断学理论与实践, 2016, 15(06): 545-549.
[8]	赵智刚, 王金焕. 骨髓微环境调控骨髓增生异常综合征的作用及相关机制[J]. 诊断学理论与实践, 2016, 15(06): 550-555.
[9]	宋陆茜, 常春康. 二代测序技术在骨髓增生异常综合征诊治中的临床应用[J]. 诊断学理论与实践, 2016, 15(06): 556-560.
[10]	肖超, 常春康. 骨髓增生异常综合征的铁过载诊断和铁螯合治疗[J]. 诊断学理论与实践, 2016, 15(06): 561-566.
[11]	杨丽艳, 王化泉. 血小板生成素受体激动剂的作用机制及其在骨髓增生异常综合征治疗中的应用[J]. 诊断学理论与实践, 2016, 15(06): 567-572.
[12]	任艳玲, 佟红艳. 骨髓增生异常综合征常用药物治疗的机制[J]. 诊断学理论与实践, 2016, 15(06): 573-577.
[13]	常春康,. 骨髓增生异常综合征WHO(2016)分型的修正[J]. 诊断学理论与实践, 2016, 15(03): 222-225.
[14]	杨希, 姜波, 冯学兵, 姚根宏, 孙凌云,. 间充质干细胞调控趋化因子配体2对系统性红斑狼疮作用的机制探讨[J]. 诊断学理论与实践, 2014, 13(03): 246-250.
[15]	常春康,. 骨髓增生异常综合征分类的演变:从FAB到WHO及将来[J]. 诊断学理论与实践, 2014, 13(01): 101-106.